Clearmind Medicine Inc. Common Shares - CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).

Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.

Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.

Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.

Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.

Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.

For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

02/20/2024 07:14 AM

News

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Rhea-AI Summary

Clearmind Medicine Inc. submits three patent applications under the PCT for novel psychedelic-derived therapeutics in collaboration with SciSparc Ltd., strengthening its IP portfolio. The company now holds 27 granted patents and 24 pending patent applications across 15 patent families.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.07%

Tags

02/05/2024 07:51 AM

News

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Rhea-AI Summary

Clearmind Medicine Inc. has been granted divisional patent approval by the China National Intellectual Property Administration, expanding its IP protection in the psychedelic space. The company's IP portfolio consists of fifteen utility patent families, including patents and applications in major jurisdictions such as the US, Europe, China, and India. The flagship molecule, MEAI, has shown promising results in regulating binge behaviors and alcohol consumption, offering potential treatment for Alcohol Use Disorder and binge drinking.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.1%

Tags

02/01/2024 08:15 AM

News

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

Rhea-AI Summary

Clearmind Medicine Inc. announced a long-term licensing agreement with BIRAD for innovative cocaine addiction treatment. The agreement secures exclusive rights to the technology, aiming to revolutionize addiction treatment. Positive pre-clinical results for the treatment of cocaine addiction using MEAI were reported, showing potential in abolishing cocaine-induced conditioned place-preference and eliminating heightened craving.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

20.28%

Tags

01/16/2024 12:20 PM

News

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Rhea-AI Summary

Aegis Capital Corp. served as the Sole Bookrunner for a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND) on January 16, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.88%

Tags

01/16/2024 11:19 AM

News

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

Rhea-AI Summary

Clearmind Medicine Inc. announced the closing of definitive agreements with institutional investors for the purchase and sale of Common Shares and Pre-Funded Warrants, raising approximately $2.4 million in gross proceeds. The Company plans to use the net proceeds for general corporate purposes and working capital. Aegis Capital Corp. acted as Exclusive Placement Agent for the offerings, and the registered direct offering was made pursuant to an effective shelf registration statement previously filed with the SEC.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.88%

Tags

01/11/2024 09:28 AM

News

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

Rhea-AI Summary

Clearmind Medicine Inc. (NASDAQ: CMND) has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering, with aggregate gross proceeds expected to be approximately $2.4 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-43%

Tags

01/10/2024 07:18 AM

News

Clearmind Medicine Completed Type A Meeting with the FDA

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) completes Type A meeting with FDA for its proprietary MEAI-based, CMND-100 compound to treat Alcohol Use Disorder (AUD). The meeting aimed to align on the content of the IND resubmission and advance the U.S. regulatory process. The active ingredient, MEAI, has shown promise in reducing alcohol consumption and providing a euphoric alcohol-like experience by interacting with serotonergic and alpha-2-adrenergic receptors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

41.55%

Tags

01/04/2024 07:18 AM

News

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Rhea-AI Summary

Clearmind Medicine Inc. (CMND) collaborates with SciSparc Ltd. (SPRC) to file six US patent applications for novel combinations of psychedelics with PEA. The collaboration aims to develop transformative medicines for mental health disorders and strengthen Clearmind's IP portfolio in the psychedelic space.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.51%

Tags

12/14/2023 08:26 AM

News

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND, CSE: CMND, FSE: CWY) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring that its common shares will continue to be listed and traded on Nasdaq.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.72%

Tags

12/05/2023 08:47 AM

News

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND, CSE: CMND, FSE: CWY) achieves positive results in addiction treatment with its innovative psychedelic molecule, MEAI, targeting cocaine addiction. The trial led by Professor Gal Yadid at Bar Ilan University in Israel showed a significant decrease in cocaine-induced craving among rats treated with MEAI. This groundbreaking research could revolutionize treatment protocols for the millions affected by cocaine addiction worldwide, offering new hope to those trapped in the cycle of addiction.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

14.1%

Tags

FAQ

What is the current stock price of Clearmind Medicine Common Shares (CMND)?

The current stock price of Clearmind Medicine Common Shares (CMND) is $1.72 as of December 24, 2024.

What is the market cap of Clearmind Medicine Common Shares (CMND)?

The market cap of Clearmind Medicine Common Shares (CMND) is approximately 7.5M.

What is Clearmind Medicine Inc.'s primary area of focus?

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and under-treated health problems, particularly alcohol use disorder (AUD).

What is CMND-100?

CMND-100 is Clearmind's flagship MEAI-based compound aimed at treating alcohol use disorder. It has shown promising pre-clinical results in reducing binge drinking without causing hallucinations.

What recent clinical developments has Clearmind made?

The Israeli Ministry of Health recently approved a Phase I/IIa clinical trial for CMND-100 to treat alcohol use disorder, marking a significant milestone in its development.

What are the key features of Clearmind's intellectual property portfolio?

Clearmind's intellectual property portfolio includes eighteen patent families and 27 granted patents, with recent additions focusing on treatments for alcohol use disorder, cocaine addiction, and obesity-related disorders.

What strategic collaborations has Clearmind entered into?

Clearmind has entered exclusive licensing agreements with the Hebrew University of Jerusalem and Yissum Research Development Company, enriching its portfolio with psychedelic compounds for treating addiction and mental health disorders.

What is Clearmind's MEAI-based alcohol substitute beverage program?

Clearmind is developing a proprietary, ethanol-free MEAI-based alcohol substitute beverage. This product aligns with the growing trend towards no- and low-alcohol consumption and aims to offer a health-focused alternative.

Where are Clearmind's shares traded?

Clearmind's shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY0'.

How can I contact Clearmind Medicine Inc. for more information?

For more information, you can visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

What is Clearmind's approach to intellectual property?

Clearmind is committed to expanding and protecting its intellectual property by filing additional patents and remaining opportunistic regarding the acquisition of new IP assets.